Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03459287 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients
A Phase 3 study, sponsored by Cerus Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 581
- Enrollment target
NCT03459287 is a Phase 3 study that has completed, run by Cerus Corporation. The registered enrollment target is 581 participants.
The verdict
NCT03459287, a Phase 3 study, has completed, sponsored by Cerus Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 581 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the efficacy and safety of RBC transfusion for support of acute anemia in cardiovascular surgery patients based on the clinical outcome of renal impairment following transfusion of red blood cells (RBCs) treated with the INTERCEPT Blood System (IBS) for Red Blood Cells compared to patients transfused with conventional RBCs.
Interventions
- DEVICE Control
- DEVICE INTERCEPT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 581 participants |
| Start Date | 2018-12-05 |
| Est. Completion | 2024-03-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03459287
The ClinicalTrials.gov registry entry for NCT03459287 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 581 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cerus Corporation, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Control is the first listed.
NCT03459287 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03459287 about?
NCT03459287 is a clinical study titled "Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients". The objective of this study is to evaluate the efficacy and safety of RBC transfusion for support of acute anemia in cardiovascular surgery patients based on the clinical outcome of renal impairment following transfusion of red blood cells (RBCs) treated with the INTERCEPT Blood System (IBS) for Red...
What is the current status of trial NCT03459287?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 581 participants. The study started on 2018-12-05. Estimated completion is 2024-03-05.
What interventions are being tested in trial NCT03459287?
The interventions under investigation include: Control (DEVICE), INTERCEPT (DEVICE).
Who is sponsoring clinical trial NCT03459287?
This trial is sponsored by Cerus Corporation, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.